2013
Notch signaling and new therapeutic options in liver disease
Morell CM, Strazzabosco M. Notch signaling and new therapeutic options in liver disease. Journal Of Hepatology 2013, 60: 885-890. PMID: 24308992, DOI: 10.1016/j.jhep.2013.11.028.Peer-Reviewed Original ResearchConceptsLiver diseaseTherapeutic agentsNew therapeutic optionsNotch signalingSpecific therapeutic agentsStem cell featuresTherapeutic optionsLiver malignanciesLiver metabolismTherapeutic relevanceAberrant activationLiver regenerationPersistent activationDiseaseAdult liverPossible targetsFurther studiesCell featuresNovel findingsRecent reportsNotch pathwayLiverCritical playersSignalingActivation
2011
Dual farnesoid X receptor/TGR5 agonist INT‐767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO output
Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert P, Trauner M. Dual farnesoid X receptor/TGR5 agonist INT‐767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO output. Hepatology 2011, 54: 1303-1312. PMID: 22006858, PMCID: PMC3744065, DOI: 10.1002/hep.24537.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine TriphosphatasesAnalysis of VarianceAnimalsAnion Transport ProteinsATP Binding Cassette Transporter, Subfamily BBile Acids and SaltsBiliary Tract DiseasesCholic AcidsDisease Models, AnimalLiver DiseasesMaleMiceMice, Inbred C57BLRandom AllocationReceptors, Cytoplasmic and NuclearReceptors, G-Protein-CoupledStatistics, NonparametricConceptsFarnesoid X receptorINT-767Liver injuryChronic cholangiopathiesTGR5 agonistsINT-747Hepatic inflammationINT-777Bile secretionBiliary bile acid outputActivation of FXRNuclear farnesoid X receptorSerum liver enzymesBile acid outputBile acid homeostasisFXR-dependent mannerBile acid synthesisMembrane G protein-coupled receptorsG protein-coupled receptorsLiver transplantationProtein-coupled receptorsBiliary fibrosisAcid outputChow dietTherapeutic options
2007
Combined Double Lung–Liver Transplantation for Cystic Fibrosis Without Cardio‐Pulmonary By‐Pass
Corno V, Dezza M, Lucianetti A, Codazzi D, Carrara B, Pinelli D, Parigi P, Guizzetti M, Strazzabosco M, Melzi M, Gaffuri G, Sonzogni V, Rossi A, Fagiuoli S, Colledan M. Combined Double Lung–Liver Transplantation for Cystic Fibrosis Without Cardio‐Pulmonary By‐Pass. American Journal Of Transplantation 2007, 7: 2433-2438. PMID: 17845577, DOI: 10.1111/j.1600-6143.2007.01945.x.Peer-Reviewed Original ResearchConceptsLung-liver transplantationCystic fibrosisExtended right graftsSitu split liversWhole liver graftsEnd-stage lungUse of CPBRight graftSplit liverLung transplantPortal hypertensionRespiratory failureLiver graftsLiver diseaseTherapeutic optionsStage lungTransplantationEffective procedureYoung menPatientsFibrosisGraftRecipientsCPBBasiliximab